These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31933797)

  • 1. LncRNA GAS6-AS2 facilitates tumor growth and metastasis of hepatocellular carcinoma by activating the PI3K/AKT/FoxO3a signaling pathway.
    Liang C; Pang L; Ke Y; Ji W; Xiong J; Ding R; Ding Y
    Int J Clin Exp Pathol; 2019; 12(11):4011-4023. PubMed ID: 31933797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA EPB41L4A-AS2 inhibits hepatocellular carcinoma development by sponging miR-301a-5p and targeting FOXL1.
    Wang YG; Wang T; Shi M; Zhai B
    J Exp Clin Cancer Res; 2019 Apr; 38(1):153. PubMed ID: 30971290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of lncRNA GAS6-AS2 alleviates sepsis-related acute kidney injury through regulating the miR-136-5p/OXSR1 axis
    Cui H; Ren G; Hu X; Xu B; Li Y; Niu Z; Mu L
    Ren Fail; 2022 Dec; 44(1):1070-1082. PubMed ID: 35793478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-34a and miR-125a-5p inhibit proliferation and metastasis but induce apoptosis in hepatocellular carcinoma cells via repressing the MACC1-mediated PI3K/AKT/mTOR pathway.
    Zhang YM; Wu QM; Chang LY; Liu JC
    Neoplasma; 2020 Sep; 67(5):1042-1053. PubMed ID: 32484698
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Li Z; Jiang M; Zhang T; Liu S
    Cancer Biother Radiopharm; 2021 Dec; 36(10):879-887. PubMed ID: 32799553
    [No Abstract]   [Full Text] [Related]  

  • 6. LncRNA HEIH Confers Cell Sorafenib Resistance in Hepatocellular Carcinoma by Regulating miR-98-5p/PI3K/AKT Pathway.
    Shen Q; Jiang S; Wu M; Zhang L; Su X; Zhao D
    Cancer Manag Res; 2020; 12():6585-6595. PubMed ID: 32821157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.
    Cao MQ; You AB; Zhu XD; Zhang W; Zhang YY; Zhang SZ; Zhang KW; Cai H; Shi WK; Li XL; Li KS; Gao DM; Ma DN; Ye BG; Wang CH; Qin CD; Sun HC; Zhang T; Tang ZY
    J Hematol Oncol; 2018 Jan; 11(1):12. PubMed ID: 29361949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA FGF14-AS2 represses proliferation, migration, invasion, and induces apoptosis in breast cancer by sponging miR-205-5p.
    Yang Y; Xun N; Wu JG
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6971-6982. PubMed ID: 31486497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA RUSC1-AS1 contributes to the progression of hepatocellular carcinoma cells by modulating miR-340-5p/CREB1 axis.
    Liu C; Tang L; Xu M; Lin Y; Shen J; Zhou L; Ho L; Lu J; Ai X
    Am J Transl Res; 2021; 13(3):1022-1036. PubMed ID: 33841637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN.
    Du W; Zhang X; Wan Z
    Onco Targets Ther; 2019; 12():4897-4906. PubMed ID: 31417285
    [No Abstract]   [Full Text] [Related]  

  • 12. MicroRNA-493-5p suppresses colorectal cancer progression via the PI3K-Akt-FoxO3a signaling pathway.
    Cui FC; Chen Y; Wu XY; Hu M; Qin WS
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4212-4223. PubMed ID: 32373957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel lncRNA SFTA1P Promotes Tumor Growth by Down-Regulating miR-4766-5p via PI3K/AKT/mTOR Signaling Pathway in Hepatocellular Carcinoma.
    Huang G; Yang Y; Lv M; Huang T; Zhan X; Kang W; Hou J
    Onco Targets Ther; 2020; 13():9759-9770. PubMed ID: 33061455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis.
    Cai M; Shao W; Yu H; Hong Y; Shi L
    Cancer Manag Res; 2020; 12():5931-5943. PubMed ID: 32765094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long Non-Coding RNA PART1 Promotes Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells via miR-149-5p/MAP2K1 Axis.
    Zhou C; Wang P; Tu M; Huang Y; Xiong F; Wu Y
    Cancer Manag Res; 2020; 12():3771-3782. PubMed ID: 32547213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA PTOV1-AS2 Promotes Colon Cancer Progression through the miR-145-5p/FSCN1 Axis.
    Zhang Z; Wu H; Chen Z; Li G; Guo J
    J Oncol; 2023; 2023():1298312. PubMed ID: 36960218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of miR-193a-5p in the proliferation and apoptosis of hepatocellular carcinoma.
    Wang JT; Wang ZH
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7233-7239. PubMed ID: 30468466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. lncRNAHIF1A-AS2 Promotes Renal Carcinoma Cell Proliferation and Migration via miR-130a-5p/ERBB2 Pathway.
    Zhu Y; Yang Z; Chen H; Pan Y; Gong L; Chen F; Jin X; Wen S; Li Y; Chen G
    Onco Targets Ther; 2020; 13():9807-9820. PubMed ID: 33061459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulated lncRNA ADAMTS9-AS2 in breast cancer enhances tamoxifen resistance by activating microRNA-130a-5p.
    Shi YF; Lu H; Wang HB
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1563-1573. PubMed ID: 30840279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor suppressor miR-139-5p targets Tspan3 and regulates the progression of acute myeloid leukemia through the PI3K/Akt pathway.
    Zhang R; Tang P; Wang F; Xing Y; Jiang Z; Chen S; Meng X; Liu L; Cao W; Zhao H; Ma P; Chen Y; An C; Sun L
    J Cell Biochem; 2019 Mar; 120(3):4423-4432. PubMed ID: 30367526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.